Recent advances using immunomodulators for inflammatory bowel disease.
about
Inflammatory pathways of importance for management of inflammatory bowel diseaseTreatment of pregnant women with a diagnosis of inflammatory bowel diseaseHuaier aqueous extract protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NLRP3 inflammasome activation.Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn's disease: a systematic review and meta-analysisThe Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-κB and MAPK signaling inactivation.The link between ankylosing spondylitis, Crohn's disease, Klebsiella, and starch consumption.Effects of Guchang Capsule on Dextran Sulphate Sodium-Induced Experimental Ulcerative Colitis in Mice.Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.LL202 protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting MAPK/AP-1 signaling.IBD medications during pregnancy and lactation.The role and advances of immunomodulator therapy for inflammatory bowel disease.Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease.Pharmacogenetics of inflammatory bowel disease.Assessment of the validity of a multigene analysis in the diagnostics of inflammatory bowel disease.
P2860
Q27005445-F7D8531C-6A44-4930-9877-E2EED37358D9Q28067821-93EDEC39-4A6A-441D-853A-923942C5199AQ33779319-7DCB91AE-B63D-4CD8-B274-9FFD90226F6DQ35679414-2D3AEADD-63CD-4093-9B04-3DAEFA5477DDQ36026672-DE5880AA-43C7-4339-9673-7F5134B12ED1Q36061829-AF16E391-897D-4A32-A7DC-319DD5EA45CDQ36918422-FA78EBB9-0FAF-4EEF-8841-2BC33AFEB188Q36973932-90D9F033-4805-42DD-BD4D-0DAE854638BBQ37620900-0B32BC61-7373-48A2-B3DD-BAB979FAAF72Q37665540-C9A2660B-1FBA-4E26-9923-B92FDB19B6DBQ38125114-17B2FE25-4CA0-4D80-929C-BCB7DACF7ADFQ38237701-6C93C5B9-0B15-4F29-875A-5E266AD978F1Q38364465-4957EAFE-BBD6-4750-AF9C-A6044B1459FEQ38563075-F5980E27-12BF-4135-9BB7-01B552F56018Q38896538-B0BBE18C-A881-42BD-99C7-4C425DAF0A6AQ41673937-4162359F-215A-4E09-8B17-B179830B9263Q44091952-F7CC871C-5E14-48F8-ABFB-6B46557E8255
P2860
Recent advances using immunomodulators for inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recent advances using immunomodulators for inflammatory bowel disease.
@en
type
label
Recent advances using immunomodulators for inflammatory bowel disease.
@en
prefLabel
Recent advances using immunomodulators for inflammatory bowel disease.
@en
P2860
P356
P1476
Recent advances using immunomodulators for inflammatory bowel disease.
@en
P2093
Hans Herfarth
Jacob Tveiten Bjerrum
P2860
P304
P356
10.1002/JCPH.2
P577
2013-02-13T00:00:00Z